

EDITORIAL

Never stand still

Thomas Wekerle & Rainer Oberbauer
Editors-in-Chief

Stagnation is viewed as a sign of impending decline. Only uninterrupted progress is regarded as a sign of a positive future. Despite the prophets of doom, a series of indicators signal that the field of transplantation as a whole and *Transplant International* in particular are healthy and strong, with a positive development ahead of them.

- The two focus issues published in 2016 highlight areas of active investigation. The series of articles on ‘donation after cardiac death’ (DCD) was edited by Rutger Ploeg [1–7] and the one on ‘vascularized composite allotransplantation’ (VCA) by Stefan Tullius [8–14]. The focus issues, together with the stand-alone review articles published in each monthly issue, are testament to the innovative vigor and the constant progress of the field. We invite you to check them out at www.transplantinternational.com.
- The most recent Impact Factor of *Transplant International* (2.835) has shown an increase over the previous year and we are optimistic that this trend will continue.

- Wiley’s Transplant Peer Review Network (Tx PRN), with *Transplant International* as one of the founding members, was successfully launched in early 2016 and continues to evolve as tool to improve the publication process for authors and to reduce the work load for reviewers.

- *Transplant International* and the European Society for Organ Transplantation (ESOT) have moved closer together. The strengthened cooperation will become especially visible through a series of activities at the upcoming 18th ESOT Congress in Barcelona from 24 to 27 September 2017 (esot2017.esot.org).

For 2017, we will strive to keep the momentum going, focusing on continuously increasing the quality of the scientific content published in *Transplant International*. We welcome your feedback, comments and suggestions at transpl-int@meduniwien.ac.at and invite you to contribute to the journal as author, reviewer and reader!

Yours sincerely,

Thomas Wekerle and Rainer Oberbauer

REFERENCES

1. Thuong M, Ruiz A, Evrard P. New classification of donation after circulatory death donors definitions and terminology. *Transpl Int* 2016; **29**: 749.
2. Murphy P, Boffa C, Manara A, Ysebaert D, de Jongh W. In-hospital logistics: what are the key aspects for succeeding in each of the steps of the process of controlled donation after circulatory death? *Transpl Int* 2016; **29**: 760.
3. Haase B, Bos M, Boffa C, et al. Ethical, legal, and societal issues and recommendations for controlled and uncontrolled DCD. *Transpl Int* 2016; **29**: 771.
4. Van Heurn LW, Talbot D, Nicholson ML, et al. Recommendations for donation after circulatory death kidney transplantation in Europe. *Transpl Int* 2016; **29**: 780.
5. Erasmus ME, van Raemdonck D, Akhtar MZ, et al. DCD lung donation: donor criteria, procedural criteria, pulmonary graft function validation, and preservation. *Transpl Int* 2016; **29**: 790.
6. Berney T, Boffa C, Augustine T, et al. Utilization of organs from donors after circulatory death for vascularized pancreas and islet of Langerhans transplantation: recommendations from an expert group. *Transpl Int* 2016; **29**: 798.
7. Domínguez-Gil B, Duranteau J, Mateos A, et al. Uncontrolled donation after circulatory death: European practices and recommendations for the development and optimization of an effective programme. *Transpl Int* 2016; **29**: 842.
8. Tullius SG. Vascular composite tissue transplantation: achievements and challenges in a rapidly developing field. *Transpl Int* 2016; **29**: 643.
9. Kaufman CL, Marvin MR, Chilton PM, et al. Immunobiology in VCA. *Transpl Int* 2016; **29**: 644.
10. Kueckelhaus M, Fischer S, Seyda M, et al. Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration. *Transpl Int* 2016; **29**: 655.
11. Schneider M, Cardones AR, Selim MA, Cendales LC. Vascularized composite allotransplantation: a closer look at the banff working classification. *Transpl Int* 2016; **29**: 663.
12. Issa F. Vascularized composite allograft-specific characteristics of immune responses. *Transpl Int* 2016; **29**: 672.
13. Glazier AK. Regulatory oversight in the United States of vascularized composite allografts. *Transpl Int* 2016; **29**: 682.
14. Samuel U. Regulatory aspects of VCA in Eurotransplant. *Transpl Int* 2016; **29**: 686.